Table 7.
Adverse events up to two years: bevacizumab vs. ranibizumab
| Ocular adverse event (CATT trial)* | Bevacizumab n = 586 |
Ranibizumab n = 599 |
RR [95% CI] Bevacizumab vs. ranibizumab |
|---|---|---|---|
| Endophthalmitis | 7 (1%) | 4 (< 1%) | 1.79 [0.53, 6.08] |
| Ocular adverse event (IVAN trial)** | Bevacizumab n = 296 |
Ranibizumab n = 314 |
RR [95% CI] Bevacizumab vs. ranibizumab |
|---|---|---|---|
| Traumatic cataract | 1 (< 1%) | 1 (< 1%) | 1.06 [0.07, 16.88] |
| Severe uveitis | 1 (< 1%) | 0 | 3.18 [0.13, 77.80] |
| Retinal detachment | 0 | 1 (< 1%) | 0.35 [0.01, 8.64] |
| Retinal pigment epithelial tear | 1 (< 1%) | 3 (< 1%) | 0.35 [0.04, 3.38] |
| Non-ocular adverse event† | Bevacizumab n = 882 |
Ranibizumab n = 913 |
RR [95% CI] Bevacizumab vs. ranibizumab |
|---|---|---|---|
| At least 1 serious adverse event | 314 (36%) | 271 (30%) | 1.20 [1.05, 1.37] |
| Death | 51 (6%) | 47 (5%) | 1.12 [0.76, 1.65] |
| Myocardial infarction | 11 (1%) | 13 (1%) | 0.88 [0.39, 1.94] |
| Stroke or cerebral infarction | 11 (1%) | 14 (2%) | 0.81 [0.37, 1.78] |
| Venous thrombotic event | 14 (2%) | 6 (< 1%) | 2.42 [0.93, 6.26] |
| Transient ischemic attack** | 1 (< 1%) | 1 (< 1%) | 1.04 [0.06, 16.52] |
| Cardiac disorders | 81 (9%) | 67 (7%) | 1.25 [0.92, 1.71] |
| Gastrointestinal disorders | 37 (4%) | 14 (2%) | 2.74 [1.49, 5.02] |
| Infections | 66 (7%) | 50 (5%) | 1.37 [0.96, 1.95] |
| Injury and procedural complications | 45 (5%) | 35 (4%) | 1.33 [0.86, 2.05] |
| Neoplasms (benign, malignant, unspecified) | 36 (4%) | 38 (4%) | 0.98 [0.63, 1.53] |
| Nervous system disorders | 44 (5%) | 43 (5%) | 1.06 [0.70, 1.60] |
| Surgical or medical procedure** | 14 (5%) | 16 (5%) | 0.91 [0.44, 1.84] |
CI: confidence interval
RR: risk ratio
*
Adverse events for endophthalmitis not reported in the IVAN 2013 study; data for CATT 2011 study only